Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).
A phase 2 open-label trial evaluated transdermal CBD for 22q11.2 deletion syndrome in children, demonstrating tolerability with preliminary behavioral improvements. While promising for this rare genetic condition, controlled trials are needed to…
Medical Use of Cannabis and Adolescent Brain Vulnerability
Adolescent cannabis brain vulnerability is a critical concern due to ongoing neurodevelopment through age 25. Medical cannabis use in teens carries risks for cognition and psychiatric outcomes. Clinicians must apply specific risk-benefit frameworks…
Does Weed Stunt Penis Growth? What the Evidence Actually Shows
Adolescent cannabis use and penile development is a common concern among parents and teens. Current evidence does not support a direct causal relationship between cannabis use and impaired penile growth. However, adolescent cannabis use carries other…
Mother Sentenced for Pressuring Child to Take THC Gummies
This case highlights the dangers of unsupervised pediatric cannabis use, especially involving THC gummies. Proper medical supervision is critical for pediatric cannabis medicine. Legal consequences arise when caregivers pressure children to consume…
Can medicinal cannabis help kids’ autism, ADHD or Tourette’s? Here’s what we know so far
Medicinal cannabis pediatric neurodevelopmental evidence remains limited but promising for autism, ADHD, and Tourette's. Current research highlights potential benefits and safety concerns. Clinicians need to guide families with evidence-based information.
Can medicinal cannabis help kids’ autism, ADHD or Tourette’s? Here’s what we know so far
Pediatric cannabis use autism research is emerging but remains limited and observational. Safety concerns for ADHD and Tourette's in kids require careful clinical consideration. Families and clinicians must weigh benefits against risks with limited data.
How Marijuana Rescheduling Could Unlock Research for Rare Diseases
Marijuana rescheduling research regulatory shift would remove key barriers to clinical trials for rare pediatric diseases. This change enables rigorous studies that families and clinicians have long awaited. It is a critical step toward evidence-based…